Literature DB >> 15273406

Inhibition of histone deacetylases.

Cheng Liu1, Dawei Xu.   

Abstract

Reversible histone acetylation, governed dynamically by histone acetyltransferases (HATs) and histone deacetylases (HDACs), plays a pivotal role in regulation of gene expression through remodeling chromatin structure. Manipulation of the equilibrium between acetylation and deacetylation of histones by specific HDAC inhibitors is thus a useful tool to study functional role(s) for histone hyper-/hypoacetylation in controlling gene transcription and many other cellular activities. By using the trans-activating effect of trichostatin A (TSA), a widely used HDAC inhibitor, on the telomerase reverse transcriptase (hTERT) gene as an example, we summarize various aspects of HDAC inhibitors and provide a general strategy for their in vitro application in studies of gene regulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273406      PMCID: PMC3623540          DOI: 10.1385/1-59259-828-5:087

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  39 in total

Review 1.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 2.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  Studies on highly metabolically active acetylation and phosphorylation of histones.

Authors:  V Jackson; A Shires; R Chalkley; D K Granner
Journal:  J Biol Chem       Date:  1975-07-10       Impact factor: 5.157

4.  Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.

Authors:  X Yang; A T Ferguson; S J Nass; D L Phillips; K A Butash; S M Wang; J G Herman; N E Davidson
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 5.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

6.  Different accessibilities in chromatin to histone acetylase.

Authors:  L S Cousens; D Gallwitz; B M Alberts
Journal:  J Biol Chem       Date:  1979-03-10       Impact factor: 5.157

Review 7.  Chromatin remodelling during development.

Authors:  Lena Ho; Gerald R Crabtree
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

Review 8.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

Review 9.  Romidepsin for the treatment of cutaneous T-cell lymphoma.

Authors:  Clara Campas-Moya
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

10.  Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation.

Authors:  Kevin Pruitt; Rebekah L Zinn; Joyce E Ohm; Kelly M McGarvey; Sung-Hae L Kang; D Neil Watkins; James G Herman; Stephen B Baylin
Journal:  PLoS Genet       Date:  2006-03-31       Impact factor: 5.917

View more
  1 in total

1.  Gene silencing associated with SWI/SNF complex loss during NSCLC development.

Authors:  Shujie Song; Vonn Walter; Mehmet Karaca; Ying Li; Christopher S Bartlett; Dominic J Smiraglia; Daniel Serber; Christopher D Sproul; Christoph Plass; Jiren Zhang; D Neil Hayes; Yanfang Zheng; Bernard E Weissman
Journal:  Mol Cancer Res       Date:  2014-01-20       Impact factor: 5.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.